Table IV.
Antitumor activity and body weight changes in mice implanted with human colorectal cancer tumors from the cell lines, Col-1 or KM20C, following treatment with S-1 and the targeted antibody, bevacizumab.
| Body weight changed
|
|||||||
|---|---|---|---|---|---|---|---|
| Tumor | Drug (mg/kg) | Treatment | Tumor volumea (mm3, mean ± SD) | TGIb (%) | GDPc (days) | (g, mean ± SD) | (%) |
| Col-1 | Control | - | 924±80 | - | 0.0 | −1.7±1.5 | −7.0 |
| S-1 (6.9) | days 1–14 | 423±43 | 54.2 | 4.1 | −2.8±1.3 | −11.0 | |
| Bevacizumab (5) | days 1, 4, 8, 11 | 546±82 | 40.9 | 2.6 | −2.8±0.8 | −11.4 | |
| S-1 + bevacizumab | 172 ± 21e | 81.3 | >9.1 | −3.0±1.5 NS | −12.3 | ||
| KM20C | Control | - | 1464±221 | - | 0.0 | 0.4±1.2 | 1.6 |
| S-1 (6.9) | days 1–14 | 826±58 | 43.6 | 3.9 | −1.7±2.3 | −6.5 | |
| Bevacizumab (5) | days 1, 4, 8, 11 | 943±96 | 35.6 | 3.1 | 0.5±1.1 | 2.1 | |
| S-1 + bevacizumab | 470±32e | 67.9 | >9.5 | −0.1±0.7 NS | −0.5 | ||
a
Tumor volume on day 15;
b
tumor growth inhibition ratio on day 15;
c
GDP is the difference in time taken for the RTV to reach 3.0 between the treated and the control groups;
d
relative body weight change between days 0 and 15;
e
overall maximal P<0.05 by closed testing procedure using the Aspin-Welch t-test; NS, overall maximal P>0.05 by closed testing procedure using the Aspin-Welch t-test; GDP, growth delay period; RTV, relative tumor volume; S-1, tegafur-gimeracil-oteracil.